Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Anything goes -- Ignore unavailable to you. Want to Upgrade?

To: musicguy who wrote (26006)	6/17/1998 11:39:00 AM
From: Lupus	Respond to of 34592

Hyal & Shire Announce Phase III Results of HyClinda(TM) MISSISSAUGA, Ont., June 17 /CNW-PRN/ - Hyal Pharmaceutical Corporation (NASDAQ/NNM:HYALF - news; TSE:HPC - news) and their development partner, Shire Pharmaceuticals Group plc, announced today the results of Shire's Phase III clinical study on the first of its HyAcne development projects: HyClinda(TM). HyClinda is an improved formulation of clindamycin (an established antibiotic agent widely used for the topical treatment of acne), utilizing Hyal Pharmaceutical Corporation's Hyaluronan Induced Targeting (HIT(TM)) Technology. HIT is a drug delivery technology based on hyaluronic acid, which is designed to maintain efficacy whilst improving tolerability and patient acceptability. HyClinda, in two strengths, was compared with Dalacin T(R) (clindamycin lotion 1%, Pharmacia and Upjohn) and a placebo formulation of HIT without the active clindamycin. A total of 375 subjects were included in the study, which was a double blind, parallel group study of 12 weeks duration. All three active treatments were statistically significantly more effective than placebo at 12 weeks (p less than 0.001), at reducing the numbers of inflamed and non-inflamed lesions. There were no statistically significant differences in efficacy between the three active treatments. The three HIT based formulations were well tolerated, and showed improvements in cosmetic acceptability producing less evidence of stinging and skin greasiness. HyClinda has been developed for outlicense to a specialist dermatology company for worldwide marketing. Discussions are already underway with a number of interested parties. Commenting today, Rolf Stahel, Chief Executive of Shire said: ''We are pleased with these results which demonstrate proof-of-principle of the HIT delivery system.'' Dr. Zenas B. Noon, Jr., Chief Executive of Hyal, concurred with Mr. Stahel and added that ''together with Solarase(TM), Hyal's product for the treatment of actinic keratosis, the results with HyClinda further validate the utility of the HIT delivery system.''' Hyal Pharmaceutical Corporation is a drug delivery development company engaged in research and development utilizing its proprietary Hyaluronan Induced Targeting (HIT(TM)) Technology and Hyaluronan Improved Liposome Technology (HILT(TM)). The Company's strategy is to commercialize its developments by outlicensing on a global basis. This news release may contain forward-looking statements relating to the future performance of Hyal. Forward-looking statements, specifically those concerning future performance, are subject to certain risks and uncertainties, and actual results may differ materially. These risks and uncertainties are detailed from time to time in the Company's filings with the appropriate securities commissions. SOURCE: Hyal Pharmaceutical Corporation --------------------------------------------------------------------------------